CA2458408A1 - Analogues de nucleoside mutagene pour le traitement d'une maladie virale - Google Patents

Analogues de nucleoside mutagene pour le traitement d'une maladie virale Download PDF

Info

Publication number
CA2458408A1
CA2458408A1 CA002458408A CA2458408A CA2458408A1 CA 2458408 A1 CA2458408 A1 CA 2458408A1 CA 002458408 A CA002458408 A CA 002458408A CA 2458408 A CA2458408 A CA 2458408A CA 2458408 A1 CA2458408 A1 CA 2458408A1
Authority
CA
Canada
Prior art keywords
substituted
virus
unsubstituted
compound
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002458408A
Other languages
English (en)
Inventor
Ling Li
Alexander Gall
Richard Daifuku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koronis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2458408A1 publication Critical patent/CA2458408A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement d'une maladie virale au moyen d'analogues de nucléoside mutagène.
CA002458408A 2001-08-24 2002-08-21 Analogues de nucleoside mutagene pour le traitement d'une maladie virale Abandoned CA2458408A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31472801P 2001-08-24 2001-08-24
US60/314,728 2001-08-24
PCT/US2002/026765 WO2003018030A1 (fr) 2001-08-24 2002-08-21 Analogues de nucleoside mutagene pour le traitement d'une maladie virale

Publications (1)

Publication Number Publication Date
CA2458408A1 true CA2458408A1 (fr) 2003-03-06

Family

ID=23221182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002458408A Abandoned CA2458408A1 (fr) 2001-08-24 2002-08-21 Analogues de nucleoside mutagene pour le traitement d'une maladie virale

Country Status (6)

Country Link
US (2) US7244717B2 (fr)
EP (1) EP1425022A4 (fr)
JP (1) JP2005505536A (fr)
AU (1) AU2002326736B2 (fr)
CA (1) CA2458408A1 (fr)
WO (1) WO2003018030A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018030A1 (fr) * 2001-08-24 2003-03-06 Koronis Pharmaceuticals, Inc. Analogues de nucleoside mutagene pour le traitement d'une maladie virale
WO2015142867A1 (fr) * 2014-03-18 2015-09-24 Stc.Unm Stimulation synergique de la cytotoxicité du 5-fluorouracile dans des cellules cancéreuses par des analogues de désoxyuridine
WO2016123397A2 (fr) * 2015-01-28 2016-08-04 Massachusetts Institute Of Technology Analogues de nucléoside mutagènes et leurs utilisations
CN116098917A (zh) * 2020-02-27 2023-05-12 河南真实生物科技有限公司 核苷类化合物在治疗冠状病毒感染性疾病中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531962B1 (fr) * 1982-08-17 1986-11-14 Sandoz Sa Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
DD279407A1 (de) * 1986-07-24 1990-06-06 Akad Wissenschaften Ddr Verfahren zur herstellung eines mittels gegen aids
SE8605503D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel medicinal use
SE8704298D0 (sv) 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
WO1989008115A1 (fr) * 1988-02-24 1989-09-08 Institut De Recherches Chimiques Et Biologiques Ap NOUVEAUX DERIVES DE LA DEOXY-2'-URIDINE SUBSTITUEE EN POSITION 5, 3' ou 5' PAR DES GROUPEMENTS alpha-AMINO ACYLES, PROCEDE POUR LEUR OBTENTION ET MEDICAMENTS LES CONTENANT
US5849482A (en) * 1988-09-28 1998-12-15 Epoch Pharmaceuticals, Inc. Crosslinking oligonucleotides
MX9203459A (es) * 1988-11-15 1992-08-01 Merrell Pharma Inc Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
US6136601A (en) * 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
US6521601B1 (en) * 1992-04-14 2003-02-18 Signal Pharmaceuticals, Inc. Method and composition for inhibition of viral replication
JP3677790B2 (ja) * 1993-08-04 2005-08-03 味の素株式会社 ヌクレオシド誘導体とその製造方法
WO1998018324A1 (fr) * 1996-10-28 1998-05-07 The University Of Washington Induction d'une mutation virale par incorporation d'analogues de ribonucleosides a defaut de codage dans un arn viral
WO2003018030A1 (fr) * 2001-08-24 2003-03-06 Koronis Pharmaceuticals, Inc. Analogues de nucleoside mutagene pour le traitement d'une maladie virale

Also Published As

Publication number Publication date
US7244717B2 (en) 2007-07-17
US20030170872A1 (en) 2003-09-11
AU2002326736B2 (en) 2007-08-02
WO2003018030A1 (fr) 2003-03-06
EP1425022A4 (fr) 2009-04-29
US20060142240A1 (en) 2006-06-29
EP1425022A1 (fr) 2004-06-09
JP2005505536A (ja) 2005-02-24
US7648967B2 (en) 2010-01-19

Similar Documents

Publication Publication Date Title
Tian et al. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic
US6063628A (en) Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
US6887707B2 (en) Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
Clercq Highlights in antiviral drug research: antivirals at the horizon
De Clercq Strategies in the design of antiviral drugs
Bonnac et al. Structure–activity relationships and design of viral mutagens and application to lethal mutagenesis
WO2007038860A2 (fr) Inhibiteurs d'odcase en tant qu'antiviraux et antibiotiques
CN101310021A (zh) 作为抗病毒剂的修饰的4’-核苷
Konstantinova et al. Favipiravir and its structural analogs: Antiviral activity and synthesis methods
US7648967B2 (en) Mutagenic nucleoside analogs for the treatment of viral disease
Al Awadh Nucleotide and nucleoside-based drugs: past, present, and future
Lavie et al. Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase
JP2024517807A (ja) ヌクレオチド及びヌクレオシド治療組成物、組合せ、並びにそれらに関連する使用
Shehzadi et al. Structure-based drug design of RdRp inhibitors against SARS-CoV-2
AU2002326736A1 (en) Mutagenic nucleoside analogs for the treatment of viral disease
WO2021155119A2 (fr) Agents thérapeutiques contre la covid-19
JP4986617B2 (ja) ヘテロアリール化合物のプロドラッグ
US20100279968A1 (en) Mutagenic Nucleoside Analogs for the Treatment of Viral Disease
Pettini et al. A focus on ebola virus polymerase: structure, functions and antiviral therapies
Ohrui A new paradigm for developing antiviral drugs exemplified by the development of supremely high anti-HIV active EFdA
IL87646A (en) Preparation for the treatment of hepatitis virus containing 1 -) 2 '- Deoxy - 2' - Fluoro - Beta - B - D - Arabino - Furanozil (- 5 - Orcil
Thames Design, Synthesis, and Biological Evaluation of Modified Acyclic Fleximer Nucleoside Analogues
Wong et al. Shaping the future of antiviral Treatment: Spotlight on Nucleobase-Containing drugs and their revolutionary impact
Pisano et al. Antiviral and antiretroviral prodrugs
Herdewijn et al. Classical antiviral agents and design of new antiviral agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued